This is an extremely speculative stock. Even for a biotech. A black swan has arrived, and if the technology is viable this is their last foreseeable chance. They have a year's worth of capital, and a few months' of re-piqued interest in nanoviricides. Let's see what they do with it.
News 
Market Data 
Discover 
